Facing a life-threatening illness like cancer, patients look to their physician for reassurance and hope. “The compassionate part of me aches to alleviate my patients’ fears,” Cleveland Clinic oncologist Mikkael Sekeres, MD, writes. But what happens when they want more certainty?
Oncologists often have to deliver bad news to their patients, but repetition doesn’t make the task any easier. Relaying complex information about test results, treatment plans, risks and survival chances is challenging, writes Cleveland Clinic oncologist Mikkael Sekeres, MD, MS — especially with patients who have comprehension difficulties.
If free drug company pens and meals can influence doctors’ prescribing patterns, what happens when there’s much more at stake — like a financial share in a newly developed drug or medical device? Industry/physician relationships can fuel innovation, but also raise complex conflict-of-interest issues, as oncologist Mikkael Sekeres, MD, MS, found when his mother-in-law sought a hip replacement.
A consortium of heart researchers is taking issue with some high-profile proposals for expanded sharing of clinical trial data. A top researcher explains their concerns and outlines an alternate proposal.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Neckties can be a liability in a medical setting — a magnet for stains, a possible germ vector, and a potential noose in the grasp of a curious toddler. But the knotted bit of silk hanging from a doctor’s collar can be an icebreaker in difficult situations, writes Cleveland Clinic oncologist Mikkael Sekeres, MD. Sometimes, it can even be a lifeline.
One of the biggest challenges cancer specialists face is determining what patients want to know about their prognosis. When delivering the bad news, there’s a fine line between best-case scenarios and statistically likely outcomes, between specifics and generalities, between faith and despair. In this New York Times column, two Cleveland Clinic oncologists wrestle with what to say and how to say it.
Medical journal editors are proposing that researchers be required to disclose de-identified patient data underlying clinical trial results. Two Cleveland Clinic oncologists warn this seemingly sensible idea could jeopardize patient privacy, reduce trial access and force untenable choices.
Simple, inexpensive changes in how emergency departments handle cancer patients who present with fever can significantly shorten those patients’ wait for antibiotic administration and decrease their hospital stay, a Cleveland Clinic study has found.
Cleveland Clinic researchers are using clinical and mutational data to enhance survival predictions for heterogeneously treated patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
A phase 2 trial of 277 patients with myelodysplastic syndromes including chronic myelomonocytic leukemias found no improvement in overall response rate with azacitidine in combination with lenalidomide or vorinostat.